You're welcome to ask an LLM that question but when I immediately followed up with it the LLM softened its language but not its conclusion, justifying this due to contemporaneous knowledge of FDA approval, the trivial cost, and portfolio management strategies.
LLM Analysis of FDA Approval and Portfolio Strategy
By
–